Numerous studies explored the therapeutic effects of erythropoietin (EPO) on
neurodegenerative diseases. Few studies provided comprehensive and latest knowledge of …

Acute kidney injury (AKI) is a health problem worldwide, but there is a lack of early
diagnostic biomarkers and target-specific treatments. Ischemia-reperfusion (IR), a major …

Preeclampsia is a severe disease of late pregnancy. Etiological factors and a pathogenetic
pattern of events still require significant clarification, but it is now recognized that a large role …

Erythropoietin (EPO) is not only an erythropoiesis hormone but also an immune-regulatory
cytokine. The receptors of EPO (EPOR) 2 and tissue-protective receptor (TPR), mediate …

Introduction: The aim of this study was to examine the effectiveness of innovative peptides
obtained by addition of polypeptide motifs with antiaggregation activity (Arg-Gly-Asp, Lys-Gly …

Background Renal fibrosis is the inevitable outcome of all progressive chronic kidney
diseases (CKD) and leads to a gradual loss of renal function. We previously reported cyclic …

Erythropoietin (EPO) is known as a hormone for erythropoiesis in response to anemia and
hypoxia. However, the effect of EPO is not only limited to hematopoietic tissue. Several …

Cyclic helix B peptide (CHBP) is a peptide derivant of erythropoietin with powerful tissue-
protective efficacies in a variety of organ injuries, but without erythropoietic effect. However …

Antibody-mediated rejection (AMR) represents a major cause of allograft dysfunction and
results in allograft failure in solid organ transplantation. Cyclic helix B peptide (CHBP) is a …

Relevance: Cardiovascular diseases continue to be the leading cause of premature adult
death. Lipid profile and atherogenesis: Dislipidaemia leads to subsequent lipid …